Clinical Trial Update: Escalating Dose Study in Healthy Volunteers With SEN0014196 [Phase 1]

View source ↗

Summary

Phase 1 escalating-dose study of SEN0014196 in healthy volunteers has completed; Huntington's disease is listed as the condition.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SEN0014196

Snippet

Sponsor: Siena Biotech S.p.A. | Conditions: Huntington's Disease | Phase 1 | Status: COMPLETED